B7-H3 (CD276), a type I transmembrane glycoprotein, has garnered significant attention due to its overexpression in a wide range of human cancers.

A landmark ruling by Japan’s IP High Court awarded record-breaking $150 million damages in the Nalfurafine (Remitch®) patent dispute. This case reshapes how pharmaceutical companies approach patent term extensions, generic entry strategies, and IP litigation risks.

YS2302018 was discovered by CSPC and has been shown to effectively prevent the formation of Lp(a).

Tirzepatide is not Lilly’s only contender in this field; its small-molecule agonist orforglipron also met primary endpoints in studies and is poised for regulatory submission and potential approval.

F.Hoffmann-La Roche(Roche) disclosed two patent applications, WO2025093625A1 and WO2025104149A1, covering a series of novel macrocyclic KRAS G12C inhibitors.

Eisbach Bio GmbH has disclosed two patent applications primarily focused on the use of ALC1 inhibitors in cancer treatment: WO2025088087A1 and WO2025088175A1.

A recent Monte Rosa patent application (WO2025090727) covers eight compounds and reveals the possible structure of MRT-9643 (CDK2 MGD) (compound 6).

Suzetrigine is the first non-opioid novel pain medication approved in over two decades for pain management; however, its efficacy appears to be limited.

Patsnap Eureka LS marks our transformation from a large language model into an intelligent AI Agent platform, purpose-built for the biopharmaceutical industry.

On June 4, 2025, the CAFC issued a precedential decision in a patent infringement case involving mRNA-based COVID-19 vaccines, addressing whether the patentee’s “custom” definition of a term constituted infringement.

Radiopharmaceuticals, which combine radioactive isotopes with specific molecular carriers, are ushering in a new era of personalized medicine.

In 2024, the field of cancer therapeutics has witnessed remarkable progress in targeting Claudin 18.2 (CLDN18.2).